

Chemical Science

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Cite this: DOI: 10.1039/c0xx00000x

www.rsc.org/xxxxxx

ARTICLE TYPE

Coordination-Triggered NO Release from a Dinitrosyl Iron Complex Leads to Anti-Inflammatory Activity†

Kelsey M. Skodje,^a Min-Young Kwon,^b Su Wol Chung,^{*b} and Eunsuk Kim^{*a}

Received (in XXX, XXX) Xth XXXXXXXXX 20XX, Accepted Xth XXXXXXXXX 20XX

DOI: 10.1039/b000000x

Dinitrosyl iron complexes (DNICs) are widely considered NO storage and donor molecules in cells. However, what induces an NO release from iron of DNICs and the subsequent biological consequences remain elusive. Chemistry and biology of the NO release activity of DNICs are reported here. Changes in redox status or coordination number of discrete N-bound DNICs, respectively [Fe(TMEDA)(NO)₂] (**1**) and [Fe(TMEDA)(NO)₂I] (**2**), can generate a meta-stable {Fe(NO)₂}⁹ DNIC, [Fe(TMEDA)(NO)₂]⁺, with ν_{NO} at 1769 and 1835 cm⁻¹ and an EPR signal at $g = 2.04$, that spontaneously releases NO in solution. The NO release activity from **2** results in the up- and down-regulation of heme oxygenase-1 (HO-1) and inducible nitric oxide synthase (iNOS), respectively, in murine RAW264.7 macrophages. Furthermore, treatment with **2** leads to downregulation of pro-inflammatory cytokines, TNF- α and IL-6, and upregulation of the anti-inflammatory cytokine, IL-10. Taken together, these results demonstrate that the appropriate control of redox and coordination chemistry of DNICs could enable them to become anti-inflammatory agents, suggesting a potential new role for cellular DNICs.

Introduction

Dinitrosyl iron complexes (DNICs) are naturally occurring iron species formed by reactions between nitric oxide (NO) and cellular non-heme iron species such as iron-sulfur clusters and labile iron pools (LIP).¹ Although the biological fate of DNICs is largely unknown, protein-bound DNICs have been observed during the activation of several regulatory proteins² while glutathione-bound DNICs have been suggested to bind to glutathione transferases (GSTs)³ and be transported via multidrug resistance-associated protein 1 (MRP1).⁴ The first *in vivo* DNICs were discovered in the 1960s,⁵ decades before the importance of NO as a signaling molecule in humans was noted. These DNICs were EPR active, cysteine bound and formulated as [Fe(NO)₂(SR)₂]⁻, {Fe(NO)₂}⁹ species in the Enemark-Feltham notation,⁶ Chart 1. S-bound DNICs of this variety are most common, but both N- and O-bound ones have been found in nature.⁷ Following the discovery of endogenous DNICs, the biological effects of exogenously added DNICs have been investigated and suggest that DNICs could become a class of drugs useful in regulating diverse physiological functions that are associated with nitric oxide.¹ For example, administration of cysteine- or glutathione-bound DNICs resulted in hypotensive effects in animal studies and clinical trials.⁸

Recognition of the biological importance of DNICs subsequently inspired chemists to study the chemical reactivity and physical properties of synthetic DNICs. These investigations have shown that the ligand environment and redox status of the {Fe(NO)₂} unit are important factors that may determine the various forms of NO (i.e., NO, NO⁺, or NO⁻) released from

DNICs.⁹ Despite a great deal of synthetic and reactivity studies, the cellular response to these well characterized DNICs has not been tested. In contrast, the water-soluble DNICs that are known to exert vasodilation^{8,10} have not been isolated in pure form, which presents significant challenges in correlating the chemical properties of DNICs to their corresponding biological effects. Because of this, we have chosen to use a synthetic DNIC whose chemical reactivity can be studied both inside and outside of a cell. Herein we report chemistry and biology of discrete DNICs that can spontaneously release NO by external stimuli such as changes in their redox status or coordination.




Chart 1 Dinitrosyl iron complexes

Results and discussion

We chose to investigate a pair of TMEDA based {Fe(NO)₂}¹⁰ and {Fe(NO)₂}⁹ DNICs for this study (**1** and **2**, Chart 1), where TMEDA = *N,N,N',N'*-tetramethylethylenediamine, because these are known stable complexes in the absence of external stimuli, which makes them an ideal system in searching for the factors that trigger NO release. The {Fe(NO)₂}¹⁰ DNIC, [Fe(TMEDA)(NO)₂] (**1**), has two characteristic NO stretching

frequencies at 1629 and 1690 cm^{-1} (blue dashed, Fig. 1A). We observed that oxidation of **1** by one equivalent of ferrocenium hexafluorophosphate (FcPF_6) leads to complete loss of its NO ligands by IR spectroscopy. During the reaction, however, it was possible to detect a new intermediate species formed by the reaction of **1** with FcPF_6 , with ν_{NO} at 1769 and 1835 cm^{-1} (red solid, Fig. 1A) before the complete loss of NO. The reversible redox couple of **1** in the cyclic voltammogram ($E_{1/2} = -527$ mV vs. Fc/Fc^+ in MeCN) suggests that a cationic





Fig. 1 (A) IR spectra (KBr) of $[\text{Fe}(\text{TMEDA})(\text{NO})_2]$ (**1**) (blue dashed), $[\text{Fe}(\text{TMEDA})(\text{NO})_2]\text{I}$ (**2**) (black dotted), and the meta-stable intermediate generated from **1**/ FcPF_6 (red solid); (B) IR spectra (KBr) of iron(II) phthalocyanine before (purple dashed) and after (green solid) exposure to headspace from **2**/ AgPF_6 reaction.



Scheme 1 Oxidation of **1** and removal of iodide from **2** result in the release of NO, which is then captured from the headspace by $(\text{Pc})\text{Fe}$.

$[\text{Fe}(\text{TMEDA})(\text{NO})_2]^+$ species would be accessible by oxidation. The EPR spectrum of the intermediate displays a strong signal at $g = 2.04$ (10 K, THF), supporting the formation of an $\{\text{Fe}(\text{NO})_2\}^9$ species. Thus, a meta-stable species generated by chemical oxidation of **1** with FcPF_6 is proposed to be a cationic $\{\text{Fe}(\text{NO})_2\}^9$ DNIC, $[\text{Fe}(\text{TMEDA})(\text{NO})_2]^+$, from which NO is released, Scheme 1. The evolution of NO gas during the reaction was further confirmed by employing an NO trapping agent, iron(II) phthalocyanine (PcFe), Scheme 1. When the headspace gas from the reaction mixture of **1** and FcPF_6 was transferred to a solution of PcFe , the formation of PcFe-NO was observed in the IR spectrum with the known ν_{NO} at 1686 cm^{-1} . The assignment of ν_{NO} was further confirmed by employing ^{15}NO labeled **1**, from which the expected shift was observed at $\nu_{^{15}\text{NO}} = 1654$ cm^{-1} ($\Delta \nu_{\text{NO}} = -32$ cm^{-1}) for $\text{PcFe-}^{15}\text{NO}$.

We anticipated that removing the iodide ligand from $[\text{Fe}(\text{TMEDA})(\text{NO})_2]\text{I}$ (**2**), a five-coordinate $\{\text{Fe}(\text{NO})_2\}^9$ compound, would generate the same meta-stable cationic $\{\text{Fe}(\text{NO})_2\}^9$ species that leads to NO release. To test this, we added one equivalent of AgPF_6 to an acetonitrile solution of **2**. This resulted in precipitation of AgI , loss of ν_{NO} at 1719 and 1777 cm^{-1} from **2**, and trapping of $\text{NO}_{(\text{g})}$ from the headspace by PcFe (Fig. 1B), as expected.

The observed properties of $[\text{Fe}(\text{TMEDA})(\text{NO})_2]\text{I}$ (**2**) subsequently led us to investigate its biological activity on living cells as a pro-drug candidate of NO releasing agent. We reasoned that **2** is a stable and inactive molecule that can be easily administered to the cell and then it can be converted to its active form, a cationic four-coordinate $\{\text{Fe}(\text{NO})_2\}^9$ species that spontaneously releases NO through ligand dissociation inside the cell. Because the chloride concentration inside a cell is significantly lower than outside, it is likely that the labile iodide ligand would dissociate upon entering the cell to form a meta-stable cationic DNIC, leading to NO release. A very similar activity is well known for the anticancer agent cisplatin, $[\text{Pt}(\text{NH}_3)_2\text{Cl}_2]$, which becomes an effective DNA damaging agent by losing its Cl^- ligand once inside the cell.¹² In the case of **2**, physiological effects due to NO release would be expected upon treatment of cells with **2**. Accordingly, we monitored changes in expression levels of heme oxygenase-1 (HO-1) and inducible nitric oxide synthase (iNOS) upon treatment of **2** because NO is known to be a potent inducer of HO-1 in macrophages and vascular cells¹³ and a negative feedback regulator of iNOS activity and expression.¹⁴

The effects of $[\text{Fe}(\text{TMEDA})(\text{NO})_2]\text{I}$ (**2**) on the protein expression levels of HO-1 and iNOS were investigated in a murine macrophage cell line. RAW 264.7 cells were treated with **2**, lipopolysaccharide (LPS), or a combination of **2** and LPS in a time- and dose-dependent manner (Fig. 2), where LPS is a bacterial virulence factor with known pro-inflammatory properties.¹⁵ The treatment of **2** resulted in the increase of the HO-1 level in the absence or the presence of LPS (Fig. 2A and 2B). On the contrary, the LPS-induced iNOS protein levels were markedly decreased by the treatment of **2** (Fig. 2A and 2B). These results are reminiscent of what was observed from cells treated with a well-known NO donor, NONOate,^{13d, 14a-c} implying that **2** likely acts as an NO donor inside the cell. In order to further support a hypothesis that the changes in HO-1 and iNOS

levels were due to the NO release from **2**, the effects of a NO-free control compound, [Fe(TMEDA)Cl₂]₂ (**3**), on the HO-1 and iNOS expression levels were also examined, in which no change was observed (Fig. 2C).¹⁶




Fig. 2 The time- and dose-dependent expression of HO-1 and iNOS protein levels in RAW 264.7 cells assessed by Western blot analyses. Dimethyl sulfoxide (DMSO) was used as a vehicle to solubilise the test compounds. (A) Time course of HO-1 and iNOS levels after administration of lipopolysaccharide (LPS) (100 ng/mL) or a combination of LPS (100 ng/mL) and [Fe(TMEDA)(NO)₂I] (**2**) (500 μM). Lane V shows protein levels in a vehicle-treated cell control; (B) Dose-dependent HO-1 and iNOS levels after exposure to varying concentrations of **2** (0, 10, 100, and 500 μM) in the absence or the presence of LPS (100 ng/mL) at 12 hours; (C) Dose-dependent HO-1 and iNOS levels after exposure to varying concentrations of [Fe(TMEDA)Cl₂]₂ (**3**) (0, 10, 100, and 500 μM) in the absence or the presence of LPS (100 ng/mL) at 12 hours. The housekeeping protein, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), was used as a loading control. These experiments were performed three independent times.




Fig. 3 Levels of mRNA for HO-1 (A) and iNOS (B) in RAW 264.7 cells assessed by quantitative real-time RT-PCR. Total RNA was extracted after administration of **2** (500 μM), LPS (100 ng/mL), or a combination of LPS + **2** at 12 hours. Expression levels of HO-1 and iNOS mRNA are divided by expression of the control gene, β-actin, and shown as a fold induction of vehicle (DMSO). The asterisk indicates significant upregulation of HO-1 mRNA expression by the treatment of LPS with **2** vs. LPS alone ($P < 0.05$). The dagger indicates significant downregulation of iNOS mRNA expression by the treatment of LPS with **2** vs. LPS alone ($P < 0.05$). For all of the real-time PCR experiments, values are presented as mean ± SD, $n=3$.




Fig. 4 The effects of [Fe(TMEDA)(NO)₂I] (**2**) on cytokine production measured by ELISA. RAW 264.7 cells were stimulated with **2** (500 μM), LPS (100 ng/mL), or a combination of LPS and **2** for 6 hours. Dimethyl sulfoxide (DMSO) was used as a vehicle for **2**. Supernatants were then analyzed for TNF-α (A), IL-6 (B), and IL-10 (C). The asterisks indicate significant downregulation of TNF-α and IL-6 production by the treatment of LPS with **2** vs. LPS alone ($P < 0.05$). The dagger indicates significant upregulation of IL-10 by the treatment of LPS with **2** vs. LPS alone ($P < 0.05$). Values are mean ± SD, $n=6$. Results are representative for three independent experiments.

The effects of [Fe(TMEDA)(NO)₂I] (**2**) on HO-1 and iNOS at the gene expression level were subsequently studied by quantitative real-time RT-PCR in RAW 264.7 cells. Upon treatment of **2** (500 μM) in the presence of LPS (100 ng/mL), mRNA expression of HO-1 was increased by 280.2±7.6% while that of iNOS was decreased by 34.9±2.6% (Fig. 3). In the absence of LPS, however, only the basal expression of HO-1 and iNOS mRNA were observed upon treatment of **2** (Fig. 3), which suggests that **2** may have post-transcriptional regulation effects on HO-1 expression in the absence of LPS.

It is well known that cytoprotective HO-1 plays a critical role in defending the body against oxidant-induced injury during inflammatory processes,¹⁷ whereas the activation of iNOS can lead to organ destruction in inflammatory diseases.¹⁸ Therefore, one can expect that [Fe(TMEDA)(NO)₂I] (**2**) would have regulatory effects on inflammation in macrophages. In order to examine such effects, the levels of well-known pro-inflammatory cytokines such as TNF-α and IL-6, and an anti-inflammatory cytokine, IL-10, were assessed upon treatment of **2**. RAW 264.7 cells were stimulated with **2** (500 μM), LPS (100 ng/mL), or a combination of **2** and LPS for 6 hours, after which supernatants were harvested and measured for TNF-α, IL-6, and IL-10 by ELISA. The results (Fig. 4) show that the LPS-induced pro-inflammatory cytokines (TNF-α and IL-6) were downregulated in the presence of **2**, whereas the production of anti-inflammatory cytokine, IL-10, was upregulated by **2**. These data strongly suggest that **2** leads to anti-inflammatory response in macrophages.

Nitric oxide (NO) is a signalling molecule involved in cardiovascular function, neural signalling, immunodefence, and apoptosis.¹⁹ Loss of endogenous NO has harmful effects that include vasoconstriction, greater smooth cell proliferation, and increased platelet and inflammatory cell activity and adherence at sites of endothelial damage.^{19,20} Because of the great physiological importance of NO and the associated medical needs, synthetic NO donors have emerged as a class of drug

useful in regulating these functions.²⁰ The present study shows that controlling coordination properties of DNICs can be a useful strategy to create a new class of therapeutic NO donors. A neutral five-coordinate {Fe(NO)₂}⁹ DNIC possessing a labile anionic ligand can be used as a pro-drug that becomes active upon entering the cell by forming a cationic DNIC that readily releases NO. One may expect that the NO releasing ability of DNICs can be systematically tailored via coordination chemistry. Possible fine-tuning of these compounds would involve changing the electronics and bite angle of the chelates to modulate the reaction rate and using hydrophilic substituents on the periphery of the chelate to increase solubility of the compounds in an aqueous medium. Some of such efforts are currently being made in our laboratory.

Conclusions

We have demonstrated previously unknown NO-donor activity of two synthetic DNICs, [Fe(TMEDA)(NO)₂] (**1**) and [Fe(TMEDA)(NO)₂I] (**2**), as well as anti-inflammatory activity of a DNIC for the first time. Chemical oxidation of **1** or removal of the iodide ligand from **2** lead to the formation of a putative 4-coordinate {Fe(NO)₂}⁹ DNIC that spontaneously releases NO in solution. When complex **2** is administered to cells, it becomes a potent regulator for HO-1 and iNOS expression in macrophages and causes anti-inflammatory effects by downregulating pro-inflammatory cytokines (TNF- α and IL-6) and upregulating an anti-inflammatory cytokine (IL-10) in macrophages. Taken together, these results show that DNICs offer promise in developing a new class of anti-inflammatory agents. Furthermore, the current finding regarding the biological effects of **2** sheds light on the possibility of a new physiological role for naturally occurring DNICs. It is conceivable that cellular DNICs may act as anti-inflammatory agents in part of the defense mechanism against oxidative/nitrosative stress.

Acknowledgements

We thank Dr. Ralph T. Weber and the Bruker BioSpin laboratory for their help with the EPR instrumentation and experiments. This research was supported by the US National Science Foundation (CHE-1254733 to EK) and the Korean government (2012M3A9C3048686 to SWC).

Notes and references

^a Department of Chemistry, Brown University, 324 Brook Street, Providence, RI 02912, United States. Fax: +1 401-863-9046; Tel: +1 401-863-3591; E-mail: eunsuk_kim@brown.edu

^b Department of Biological Sciences, University of Ulsan 93 Daehak-ro, Nam-gu, Ulsan 680-749, Korea. Fax: +82 52-259-1694; Tel: +82 52-259-2353; E-mail: swchung@ulsan.ac.kr

† Electronic Supplementary Information (ESI) available: Details of the chemical and biological experimental procedures along with IR and EPR spectroscopic data. See DOI: 10.1039/b000000x/

1 (a) H. Lewandowska, M. Kalinowska, K. Brzoska, K. Wojciuk, G. Wojciuk and M. Kruszewski, *Dalton Trans.* 2011, **40**, 8273; (b) A. F. Vanin, *Nitric Oxide* 2009, **21**, 1.

- 2 (a) H. Cruz-Ramos, J. Crack, G. Wu, M. N. Hughes, C. Scott, A. J. Thomson, J. Green and R. K. Poole, *EMBO J* 2002, **21**, 3235; (b) H. Ding and B. Demple, *Proc. Natl. Acad. Sci. U.S.A.* 2000, **97**, 5146; (c) N. P. Tucker, M. G. Hicks, T. A. Clarke, J. C. Crack, G. Chandra, N. E. Le Brun, R. Dixon and M. I. Hutchings, *PLoS one* 2008, **3**, e3623; (d) E. T. Yukl, M. A. Elbaz, M. M. Nakano and P. Moenne-Loccoz, *Biochemistry*, 2008, **47**, 13084.
- 3 (a) M. Lo Bello, M. Nuccetelli, A. M. Caccuri, L. Stella, M. W. Parker, J. Rossjohn, W. J. McKinstry, A. F. Mozzi, G. Federici, F. Polizio, J. Z. Pedersen and G. Ricci, *J. Biol. Chem.* 2001, **276**, 42138; (b) F. De Maria, J. Z. Pedersen, A. M. Caccuri, G. Antonini, P. Turella, L. Stella, M. Lo Bello, G. Federici and G. Ricci, *J. Biol. Chem.* 2003, **278**, 42283.
- 4 (a) H. C. Lok, Y. Suryo Rahmanto, C. L. Hawkins, D. S. Kalinowski, C. S. Morrow, A. J. Townsend, P. Ponka and D. R. Richardson, *J. Biol. Chem.* 2011, **287**, 607; (b) R. N. Watts, C. Hawkins, P. Ponka and D. R. Richardson, *Proc. Natl. Acad. Sci. U.S.A.* 2006, **103**, 7670.
- 5 (a) J. R. Mallard and M. Kent, *Nature* 1964, **204**, 1192; (b) A. J. Vithayathil, J. L. Ternberg and B. Commoner, *Nature* 1965, **207**, 1246; (c) A. F. Vanin, R. M. Nalbandian, *Biofizika* 1965, **10**, 167.
- 6 J. H. Enemark and R. D. Feltham, *Coord. Chem. Rev.* 1974, **13**, 339.
- 7 (a) E. Cesareo, L. J. Parker, J. Z. Pedersen, M. Nuccetelli, A. P. Mazzetti, A. Pastore, G. Federici, A. M. Caccuri, G. Ricci, J. J. Adams, M. W. Parker and M. Lo Bello, *J. Biol. Chem.* 2005, **280**, 42172; (b) B. D'Autreaux, O. Horner, J. L. Oddou, C. Jeandey, S. Gambarelli, C. Berthomieu, J. M. Latour and I. Michaud-Soret, *J. Am. Chem. Soc.* 2004, **126**, 6005; (c) M. C. Kennedy, W. E. Antholine and H. Beinert, *J. Biol. Chem.* 1997, **272**, 20340; (d) M. Lee, P. Arosio, A. Cozzi and N. D. Chasteen, *Biochemistry*, 1994, **33**, 3679.
- 8 E. I. Chazov, O. V. Rodnenkov, A. V. Zorin, V. L. Lakomkin, V. V. Gramovich, O. N. Vyborov, A. G. Dragnev, C. A. Timoshin, L. I. Buryachkovskaya, A. A. Abramov, V. P. Massenko, E. V. Arzamastsev, V. I. Kapelko and A. F. Vanin, *Nitric Oxide*, 2012, **26**, 148.
- 9 (a) C. Y. Chiang, M. L. Miller, J. H. Reibenspies and M. Y. Darensbourg, *J. Am. Chem. Soc.* 2004, **126**, 10867; (b) C. H. Hsieh, S. M. Brothers, J. H. Reibenspies, M. B. Hall, C. V. Popescu and M. Y. Darensbourg, *Inorg. Chem.* 2013, **52**, 2119; (c) T. T. Lu, C. H. Chen and W. F. Liaw, *Chem. Eur. J.* 2010, **16**, 8088; (d) T. T. Lu, S. H. Lai, Y. W. Li, I. J. Hsu, L. Y. Jang, J. F. Lee, I. C. Chen and W. F. Liaw, *Inorg. Chem.* 2011, **50**, 5396; (e) W. C. Shih, T. T. Lu, L. B. Yang, F. T. Tsai, M. H. Chiang, J. F. Lee, Y. W. Chiang and W. F. Liaw, *J. Inorg. Biochem.* 2012, **113**, 83; (f) Z. J. Tonzetich, F. Heroguel, L. H. Do and S. J. Lippard, *Inorg. Chem.* 2011, **50**, 1570.
- 10 (a) Y. P. Vedernikov, P. I. Mordvintsev, I. V. Malenkova and A. F. Vanin, *Eur. J. Pharmacol.* 1992, **211**, 313; (b) A. F. Vanin, V. P. Mokh, V. A. Serezhnikov and E. I. Chazov, *Nitric Oxide*, 2007, **16**, 322; (c) V. L. Lakomkin, A. F. Vanin, A. A. Timoshin, V. I. Kapelko and E. I. Chazov, *Nitric Oxide*, 2007, **16**, 413.
- 11 (a) C. Ercolani and C. Neri, *J. Chem. Soc. A* 1967, 1715; (b) C. Ercolani, C. Neri and G. Sartori, *J. Chem. Soc. A* 1968, 2123.
- 12 L. Kelland, *Nat. Rev. Cancer* 2007, **7**, 573-584.
- 13 (a) W. Durante, M. H. Kroll, N. Christodoulides, K. J. Peyton and A. I. Schafer, *Circ Res* 1997, **80**, 557; (b) C. Bouton and B. Demple, *J. Biol. Chem.*, 2000, **275**, 32688; (c) H. T. Chung, B. M. Choi, Y. G. Kwon and Y. M. Kim, *Methods Enzymol.*, 2008, **441**, 329; (d) C. L. Hartsfield, J. Alam, J. L. Cook and A. M. K. Choi, *Am. J. Physiol.* 1997, **273**, L980.
- 14 (a) J. M. Griscavage, A. J. Hobbs and L. J. Ignarro, *Adv. Pharmacol.*, 1995, **34**, 215; (b) S. Mariotto, M. Menegazzi and H. Suzuki, *Curr. Pharm. Des.* 2004, **10**, 1627; (c) M. Menegazzi and H. Suzuki, *Curr. Pharm. Des.* 2004, **10**, 1627.
- 15 Y. C. Lu, W. C. Yeh and P. S. Ohashi, *Cytokine*, 2008, **42**, 145.
- 16 Complexes **2** and **3** are non-toxic under the current experimental conditions, as judged by the cell viability test using the MTS assay. See further details in the Supporting Information.
- 17 (a) T. S. Lee and L. Y. Chau, *Nat. Med.* 2002, **8**, 240; (b) S. W. Chung, X. Liu, A. A. Macias, R. M. Baron and M. A. Perrella, *J. Clin. Invest.* 2008, **118**, 239.

-
- 18 (a) A. Murakami and H. Ohigashi, *Int. J. Cancer*. 2007, **121**, 2357; (b) E. Esposito and S. Cuzzocrea, *Curr. Opin. Investig Drugs*. 2007, **8**, 899.
- 19 (a) L. J. Ignarro, *J. Physiol. Pharmacol.* 2002, **53**, 505; (b) F. Murad, *N. Engl. J. Med.* 2006, **355**, 2003; (c) D. Tousoulis, A.-M. Kampoli, C. T. N. Papageorgiou and C. Stefanadis, *Curr. Vasc. Pharmacol.* 2012, **10**, 4; (d) J. S. Stamler, S. Lames and F. C. Fang, *Cell*, 2001, **106**, 675.
- 20 (a) M. R. Miller, I. L. Megson, *Br. J. Pharmacol.* 2007, **151**, 305; (b) L. J. Ignarro, C. Napoli and J. Loscalzo, *Cir. Res.*, 2002, **90**, 21; (c) D. R. Janero. *Free Radic. Biol. Med.* 2000, **10**, 1495.